NervGen Pharma Corp. (NASDAQ:NGEN) officially began trading on the Nasdaq Stock Market on January 8, marking a transition into a late-stage biopharmaceutical player.
The Vancouver-based company, which focuses on neuroreparative therapeutics, leveraged a series of clinical successes in late 2025 to secure the listing, aiming to attract a broader base of institutional investors as it nears commercialization pathways.
The Nasdaq debut follows the release of expanded Phase 1b/2a CONNECT SCI study data on November 24, 2025, which provided what management described as "unprecedented" evidence of neurorepair.
The trial, involving participants with chronic spinal cord injury (SCI), met its primary endpoint by demonstrating a statistically significant, three-fold increase in corticospinal signaling—the electrical "bridge" between the brain and muscles.
Beyond the electrophysiology, the data revealed tangible quality-of-life gains.
Patients receiving the lead candidate, NVG-291, reported a 2.6-fold greater improvement in hand and arm function (GRASSP scores) compared to the placebo group.
Notably, 67% of treated participants saw improved bladder control, addressing one of the most significant medical burdens for those living with chronic SCI.
The company is now preparing for a critical End-of-Phase 2 meeting with the FDA in early 2026.
This meeting will be pivotal in finalizing the design of a Phase 3 study, currently slated to begin enrollment in mid-2026.
If successful, NVG-291 would become the first approved pharmacologic therapy to actively repair the nervous system after a traumatic injury.